Nigeria took a major step forward in its fight against HIV/AIDS last month with the official launch of Lenacapavir, a groundbreaking injectable medicine that provides six months of protection against the virus with a single dose.
The introduction of the twice-yearly injection, administered for the first time at a ceremony in Abuja themed “Flagging off the future of HIV prevention,” represents one of the most significant advancements in HIV prevention science in the past decade and could reshape how Nigeria — and eventually the wider continent — tackles its HIV epidemic.
Until now, the standard of prevention for high-risk populations in Nigeria has been daily oral medication, commonly known as PrEP (Pre-Exposure Prophylaxis). While effective when taken consistently, PrEP’s requirement for daily adherence has proven a significant barrier in communities where stigma, access to healthcare, and socioeconomic factors make consistent pill-taking difficult. Lenacapavir’s extended duration of protection addresses this compliance challenge directly.
A Scientific Milestone
Lenacapavir, developed by Gilead Sciences, works differently from previous prevention drugs. Rather than requiring daily dosing to maintain protective levels in the bloodstream, it establishes a long-acting reservoir in the body that continuously releases the drug over a six-month period. This mechanism of action has produced remarkable results in clinical trials.
In a major study published in the New England Journal of Medicine, twice-yearly Lenacapavir demonstrated near-complete protection against HIV infection, including zero infections recorded among participants who received the injection on schedule in one pivotal trial. By contrast, participants taking daily oral PrEP in the same study showed a meaningfully higher incidence of infection, largely attributed to inconsistent adherence.
The drug is specifically designed for prevention in HIV-negative individuals. Speaking at the launch event, Adedolapo Fasawe, Mandate Secretary for Health and Environment in Nigeria’s Federal Capital Territory, emphasized that recipients must test negative for HIV before receiving the injection. “If you’re positive, the medicine doesn’t work and may even be injurious to your health,” she told attendees.
Expanding Access and Overcoming Barriers
Nigeria carries one of the highest burdens of HIV in the world, with an estimated 1.8 million people living with the virus. Despite significant progress in expanding antiretroviral therapy access over the past two decades, new infection rates have remained stubbornly high, particularly among young women, key populations, and underserved communities in the country’s north.
The injection will be administered free of charge at designated public health facilities — not through private pharmacies — in the first phase of the rollout. Health officials say they are prioritizing high-incidence communities and populations that face the greatest barriers to daily medication adherence. The federal ministry of health has partnered with Global South World, the National AIDS Control Programme, and several civil society organizations to manage distribution and community outreach.
Demand has already outpaced supply in the early weeks of the programme. Several health facilities reported waiting lists within days of the launch, with community organizations calling on the federal government to accelerate procurement.
Why This Matters for the Continent
Nigeria’s rollout is being watched closely by health authorities across Africa. The continent as a whole carries roughly 25 million people living with HIV, and prevention efforts have long been hampered by the same structural challenges Nigeria faces: stigma, weak health systems, limited laboratory capacity for regular HIV testing before starting prevention methods, and cultural and social barriers that make daily pill-taking difficult to sustain.
The twice-yearly format of Lenacapavir addresses these barriers at a structural level. A person who receives the injection in January does not need to think about HIV prevention again until July. For adolescents and young women who may not be able to negotiate condom use or daily pill schedules with partners, a twice-yearly clinical appointment offers predictability and confidentiality that a daily pill regimen cannot.
The WHO has signalled interest in快步 tracking an expedited review of Lenacapavir for global prequalification, which would enable bulk procurement through mechanisms like the Global Fund to Fight AIDS, Tuberculosis and Malaria. South Africa, Kenya, and Uganda have already signalled interest in conducting their own regulatory reviews and pilot programmes.
Sustaining the Momentum
The scientific achievement of Lenacapavir is not in doubt. What will determine whether it truly transforms Nigeria’s HIV prevention landscape is the health system’s ability to deliver it at scale — reaching the people most at risk, without stigma, without cost barriers, and without interruption.
For now, Nigeria has demonstrated what political will and international partnership can make possible. The challenge now is to translate the fanfare of a launch event into the unglamorous, grinding work of sustained health system delivery. That, more than any single injection, will determine the future of Nigeria’s HIV epidemic.